$2.40
10.60% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
US56600D1072
Symbol
MRVI

Maravai LifeSciences Stock price

$2.40
+0.63 35.59% 1M
-2.42 50.21% 6M
-3.05 55.96% YTD
-8.94 78.84% 1Y
-31.18 92.85% 3Y
-27.45 91.96% 5Y
-27.45 91.96% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.23 10.60%
ISIN
US56600D1072
Symbol
MRVI
Sector
Industry

Key metrics

Market capitalization $345.54m
Enterprise Value $616.80m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.55
P/S ratio (TTM) P/S ratio 1.43
P/B ratio (TTM) P/B ratio 1.15
Revenue growth (TTM) Revenue growth -11.76%
Revenue (TTM) Revenue $241.86m
EBIT (operating result TTM) EBIT $-84.50m
Free Cash Flow (TTM) Free Cash Flow $-23.93m
Cash position $285.05m
EPS (TTM) EPS $-1.15
P/E forward negative
P/S forward 1.78
EV/Sales forward 3.17
Short interest 11.77%
Show more

Is Maravai LifeSciences a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Maravai LifeSciences Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Maravai LifeSciences forecast:

7x Buy
47%
7x Hold
47%
1x Sell
7%

Analyst Opinions

15 Analysts have issued a Maravai LifeSciences forecast:

Buy
47%
Hold
47%
Sell
7%

Financial data from Maravai LifeSciences

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
242 242
12% 12%
100%
- Direct Costs 167 167
3% 3%
69%
75 75
33% 33%
31%
- Selling and Administrative Expenses 83 83
5% 5%
34%
- Research and Development Expense 19 19
5% 5%
8%
-26 -26
279% 279%
-11%
- Depreciation and Amortization 58 58
12% 12%
24%
EBIT (Operating Income) EBIT -84 -84
129% 129%
-35%
Net Profit -163 -163
24% 24%
-67%

In millions USD.

Don't miss a Thing! We will send you all news about Maravai LifeSciences directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Maravai LifeSciences Stock News

Neutral
Business Wire
about 16 hours ago
SAN DIEGO--(BUSINESS WIRE)--TriLink BioTechnologies® (TriLink®), a Maravai® LifeSciences company (NASDAQ: MRVI), is fueling the future of mRNA research — starting with a significant donation to top academic labs across the U.S. and Europe. The donation commemorates the launch of TriLink's first mRNA synthesis kit featuring CleanCap® capping technology, an all-in-one kit with its innovative prod...
Neutral
Seeking Alpha
8 days ago
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI ) Q1 2025 Earnings Conference Call May 12, 2025 5:00 PM ET Company Participants Debra Hart - Head, IR Kevin Herde - EVP and CFO Trey Martin - CEO Becky Buzzeo - EVP & CCO Conference Call Participants Conor McNamara - RBC Capital Markets Daniel Arias - Stifel Tejas Savant - Morgan Stanley Matthew Stanton - Jeffries Brandon Coulliard - Wells Fargo ...
Neutral
GlobeNewsWire
8 days ago
SAN DIEGO, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the first quarter ended March 31, 2025, together with other business updates.
More Maravai LifeSciences News

Company Profile

Maravai Lifesciences Holdings, Inc. operates as an investment holding company. It develops biopharmaceuticals. The company is headquartered in San Diego, CA.

Head office United States
CEO William Martin
Employees 570
Founded 2014
Website www.maravai.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today